Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes2014 · 209 citations
2. 2The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure2018 · 355 citations
3. 3SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials2018 · 2,828 citations
4. 4Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial2017 · 374 citations
5. 5Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus2019 · 565 citations